Needham & Company LLC reissued their hold rating on shares of Mazor Robotics Ltd. (NASDAQ:MZOR) in a report released on Wednesday morning.

“MZOR is entering the second phase of its partnership with MDT which consists of an additional equity investment by MDT of $40M and MDT assuming global distribution of the Mazor X. We think the agreement is positive for MZOR and MDT and negative for NUVA.”,” the firm’s analyst commented.

MZOR has been the topic of a number of other reports. Zacks Investment Research lowered shares of Mazor Robotics from a hold rating to a sell rating in a report on Tuesday, July 18th. Wells Fargo & Company lowered shares of Mazor Robotics from an outperform rating to a market perform rating in a research note on Thursday, May 11th. ValuEngine raised shares of Mazor Robotics from a sell rating to a hold rating in a research note on Friday, June 2nd. Ladenburg Thalmann Financial Services reaffirmed a buy rating and issued a $46.00 price objective on shares of Mazor Robotics in a research note on Monday, June 12th. Finally, First Analysis lowered shares of Mazor Robotics from an overweight rating to an equal weight rating and upped their price objective for the company from $28.00 to $38.00 in a research note on Thursday, May 11th. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $37.33.

Shares of Mazor Robotics (MZOR) traded up 4.15% during trading on Wednesday, reaching $49.23. 301,746 shares of the company’s stock were exchanged. Mazor Robotics has a 52-week low of $20.19 and a 52-week high of $49.64. The stock’s 50 day moving average price is $39.58 and its 200-day moving average price is $34.25. The stock’s market cap is $1.19 billion.

Mazor Robotics (NASDAQ:MZOR) last posted its earnings results on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.09. Mazor Robotics had a negative net margin of 37.66% and a negative return on equity of 28.51%. The firm had revenue of $15.46 million for the quarter, compared to analyst estimates of $15.38 million. During the same period in the previous year, the firm posted ($0.09) EPS. The company’s revenue for the quarter was up 86.7% compared to the same quarter last year. On average, equities research analysts forecast that Mazor Robotics will post ($0.75) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.watchlistnews.com/mazor-robotics-ltd-mzor-earns-hold-rating-from-needham-company-llc/1538207.html.

Large investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its stake in Mazor Robotics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock worth $296,000 after buying an additional 641 shares in the last quarter. Royal Bank of Canada raised its stake in Mazor Robotics by 9.2% in the second quarter. Royal Bank of Canada now owns 21,663 shares of the medical instruments supplier’s stock worth $749,000 after buying an additional 1,819 shares in the last quarter. UBS Group AG raised its stake in Mazor Robotics by 2.4% in the first quarter. UBS Group AG now owns 99,954 shares of the medical instruments supplier’s stock worth $2,976,000 after buying an additional 2,379 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Mazor Robotics during the second quarter worth approximately $135,000. Finally, JPMorgan Chase & Co. raised its stake in Mazor Robotics by 398.5% in the first quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock worth $208,000 after buying an additional 5,579 shares in the last quarter. 27.52% of the stock is currently owned by institutional investors.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Analyst Recommendations for Mazor Robotics (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.